Introduction
Data integrity is essential for maintaining quality, safety, and regulatory compliance in the pharmaceutical industry. As pharmaceutical companies increasingly use artificial intelligence (AI) and machine learning (ML), protecting the accuracy, completeness, consistency, and traceability of data has become more important than ever.
AI systems depend on data to generate predictions, identify patterns, support quality decisions, and automate specific processes. However, poor-quality training data, incomplete records, unauthorized changes, and weak documentation can affect the reliability of AI-generated results.
These issues can create challenges for organizations operating under Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), and other GxP requirements.
AI data integrity risks in pharma require careful assessment because problems may not always be visible through routine system checks. A model can produce convincing results even when its underlying data is incomplete, biased, outdated, or incorrectly processed.
GxP audits help pharmaceutical organizations identify these weaknesses, review supporting evidence, and determine whether appropriate controls are in place. GxP Cellators supports organizations through specialized GxP auditing services, including reviews of AI-related data integrity risks.
What Are AI Data Integrity Risks in Pharma?
AI data integrity risks are problems that affect the accuracy, completeness, reliability, traceability, or security of data used by AI systems.
These risks can arise during data collection, model training, data processing, system operation, or model updates. They may also occur when organizations lack clear procedures for reviewing AI-generated outputs and documenting human decisions.
For example, an AI tool used to identify unusual manufacturing results may provide unreliable recommendations if it receives incomplete process data. Similarly, an AI application used in quality control may produce misleading results if its training data does not adequately represent real operating conditions.
In regulated environments, companies need appropriate documentation, access controls, audit trails, change management, and human oversight based on the system’s intended use and risk.
Five Major AI Data Integrity Risks and How GxP Audits Identify Them
1. Poor Training Data Quality
Training data quality is one of the most important factors affecting AI reliability. If a model is trained using inaccurate, incomplete, duplicated, or unrepresentative data, its outputs may be misleading.
In pharmaceutical operations, this could affect applications used for manufacturing analysis, laboratory investigations, quality monitoring, or predictive maintenance.
For example, an AI model trained using incomplete manufacturing records may fail to identify a recurring process deviation.
How GxP audits identify this risk:
- Review training data sources and their suitability for the intended use.
- Assess data completeness, accuracy, consistency, and representativeness.
- Examine missing values, duplicate records, and data preprocessing activities.
- Review documentation supporting data cleaning and transformation.
- Verify that identified data quality issues are evaluated and addressed.
These checks help organizations understand whether the data supporting an AI application is appropriate for its intended purpose.
2. Missing Training Data Provenance and Traceability
Data provenance explains where data originated, how it was collected, and what changes occurred before it was used by an AI model.
Without sufficient provenance records, an organization may struggle to demonstrate that its training data came from appropriate sources or was processed using controlled procedures.
This becomes particularly important when data is collected from multiple systems, external providers, laboratory platforms, or manufacturing databases.
How GxP audits identify this risk:
- Review records identifying original data sources.
- Assess data lineage and traceability documentation.
- Examine data transfer and transformation procedures.
- Verify source qualification and approval where applicable.
- Check whether relevant data versions can be identified and reconstructed.
A documented data trail helps organizations investigate unexpected outputs and explain how information was used to develop or operate an AI model.
3. Operational Data Integrity Issues
AI data integrity risks can continue after a model has been deployed. Operational problems may arise when data is transferred incorrectly, modified without authorization, lost during processing, or recorded without sufficient traceability.
For example, an AI system monitoring production equipment may receive incorrect sensor readings because of a data integration problem. As a result, the system could generate inaccurate alerts or recommendations.
How GxP audits identify this risk:
- Review audit trails for relevant AI inputs, outputs, and changes.
- Assess user access permissions and authorization controls.
- Examine data backup and recovery procedures.
- Review data transfer interfaces and integration controls.
- Evaluate data integrity monitoring and incident management.
- Check whether discrepancies are investigated and documented.
Auditors should also determine whether controls are appropriate for the system’s intended use and the potential impact of incorrect information on product quality or patient safety.
4. Inadequate Model Change Documentation
AI models and their supporting systems may change over time. Updates can affect training datasets, model parameters, algorithms, software components, interfaces, and intended functionality.
If these changes are not properly documented, organizations may find it difficult to determine which model version generated a particular result or whether an update affected system performance.
In regulated pharmaceutical environments, uncontrolled changes can create significant compliance and traceability concerns.
How GxP audits identify this risk:
- Review model version histories and change records.
- Assess change control procedures and approval requirements.
- Examine the documented impact assessments for model updates.
- Verify testing and validation evidence following significant changes.
- Review criteria for determining when revalidation or additional testing is required.
- Confirm that previous versions and relevant records remain traceable where necessary.
A risk-based change management process helps ensure that AI system modifications are evaluated, approved, tested, and documented before implementation, as appropriate.
5. Weak Human Oversight Documentation
AI systems may support important decisions, but organizations must establish appropriate oversight based on the system’s intended use and risk. Human review is especially important when AI outputs influence quality investigations, manufacturing decisions, laboratory assessments, or other GxP activities.
Problems can arise when employees accept AI recommendations without sufficient review or when decisions to override, reject, or escalate an output are not documented.
How GxP audits identify this risk:
- Review procedures defining human responsibilities and review requirements.
- Assess records of human interventions and decisions.
- Examine training records for employees using AI applications.
- Verify escalation procedures for unexpected or unreliable outputs.
- Review evidence that critical AI-generated recommendations receive appropriate review.
- Assess how disagreements between AI outputs and human assessments are handled.
Clear responsibilities and appropriate documentation help maintain accountability when AI tools support regulated activities.
How GxP Audits Help Identify AI Data Integrity Problems
A structured GxP audit examines more than the technical performance of an AI application. It also evaluates the controls, procedures, records, and responsibilities that support its use in a regulated environment.
Depending on the application and audit scope, the assessment may include the following activities.
Review of Data Governance
Auditors assess whether data ownership, access, retention, processing, and quality responsibilities are clearly defined. They also examine whether relevant procedures are documented and followed.
Assessment of Audit Trails and Access Controls
Audit trail reviews help determine whether relevant activities and changes are traceable. Access control assessments examine whether users have appropriate permissions and whether unauthorized changes are adequately restricted.
Review of Validation and Change Control
Auditors examine the evidence supporting the AI system’s intended use, including relevant testing, validation, change assessments, and ongoing monitoring. The depth of review should reflect the system’s risk and applicable regulatory requirements.
Evaluation of Deviations and CAPA
When data integrity issues are identified, auditors review how the organization investigates the problem, evaluates its impact, determines the root cause, and implements corrective and preventive actions (CAPA).
Follow-up activities can help determine whether corrective actions were implemented effectively and whether the underlying issue has been adequately addressed.
How GxP Cellators Supports AI Data Integrity Audits
GxP Cellators provides GxP auditing and compliance support for organizations working in regulated industries. For companies adopting AI in pharmaceutical operations, an appropriately scoped audit can help identify weaknesses in data governance, documentation, traceability, and control processes.
AI-related audit support may include:
- Training data quality audits.
- Training data provenance and traceability reviews.
- Operational data integrity assessments.
- Model change documentation reviews.
- Human oversight documentation reviews.
- Audit trail and access control reviews.
- Mock AI audits and inspection readiness assessments.
- CAPA verification and follow-up activities.
The scope of each engagement should reflect the organization’s AI application, intended use, relevant GxP processes, and applicable regulatory expectations.
Why Choose GxP Cellators?
Organizations need practical findings that help them understand their compliance risks and determine appropriate next steps.
GxP Cellators supports this process through:
- GxP-focused expertise: Assessments aligned with the relevant quality and compliance environment.
- Risk-based audit planning: Audit activities tailored to the intended use and potential impact of the AI application.
- Regulatory awareness: Consideration of applicable FDA, EMA, Health Canada, MHRA, and WHO requirements and guidance.
- Actionable findings: Clear observations that help organizations prioritize remediation.
- Confidentiality: Appropriate protection of proprietary information and audit documentation.
The exact audit scope and applicable regulatory expectations should be confirmed for each engagement.
Best Practices for Managing AI Data Integrity Risks
Pharmaceutical organizations can strengthen AI data integrity by establishing clear controls throughout the system lifecycle.
- Define data quality requirements: Establish suitable criteria for data accuracy, completeness, consistency, and representativeness.
- Maintain data traceability: Document data sources, transformations, relevant versions, and processing activities.
- Apply access controls: Restrict system and data access according to assigned responsibilities.
- Maintain appropriate audit trails: Ensure relevant changes and activities can be reconstructed where required.
- Control model changes: Assess, approve, test, and document changes according to risk and established procedures.
- Provide employee training: Ensure personnel understand AI limitations, data integrity responsibilities, and escalation procedures.
- Review incidents and deviations: Investigate unexpected results and implement suitable corrective actions.
- Conduct periodic risk-based audits: Reassess controls when systems, data sources, intended uses, or regulatory expectations change.
These practices can help organizations improve oversight and identify weaknesses before they lead to more significant compliance problems.
Frequently Asked Questions
What are the main AI data integrity risks in pharma?
The main risks include poor training data quality, missing data provenance, operational data integrity problems, inadequate model change documentation, and weak human oversight. These issues can affect AI reliability, traceability, and GxP compliance.
How can GxP audits identify AI data integrity risks?
GxP audits can identify these risks by reviewing training data sources, data lineage, audit trails, access controls, model change records, validation evidence, and human oversight procedures. Auditors can also evaluate deviation investigations and CAPA effectiveness.
Why is training data quality important for pharmaceutical AI systems?
Training data quality affects how reliably an AI model identifies patterns and generates outputs. Inaccurate, incomplete, or unrepresentative data can lead to unreliable recommendations and may affect decisions involving pharmaceutical quality or regulated processes.
What is data provenance in AI auditing?
Data provenance documents where data originated, how it was processed, and how it changed before being used by an AI system. It supports traceability and helps organizations investigate unexpected outputs or demonstrate appropriate data governance.
How does GxP Cellators support AI data integrity audits?
GxP Cellators offers GxP auditing and compliance support that may include training data quality reviews, provenance assessments, operational data integrity audits, model change documentation reviews, audit trail assessments, and CAPA follow-up, depending on the agreed scope.
How can I contact GxP Cellators for AI data integrity audit support?
Visit the GxP Cellators to discuss your organization’s AI data integrity risks, audit requirements, and compliance objectives.
Contact GxP Cellators
AI adoption can create new opportunities for pharmaceutical organizations, but it also requires appropriate controls over data, documentation, and decision-making. A structured, risk-based GxP audit can help identify weaknesses and support effective remediation.
If your organization needs assistance reviewing AI data integrity risks, training data traceability, model change documentation, or related GxP controls, contact GxP Cellators to discuss your requirements.
